Figure 3. In Vitro Response to Co-inhibition of MAPK and mTOR pathways in Isogenic Mouse BRAF^V600E and BRAF^WT Cells.

Assessments of isogenic murine (A–B) BRAF^V600E and (C–D) BRAF^WT cells in response to treatment with AZD6244 + everolimus, everolimus + PLX4720 or AZD6244 + PLX4720. (A, C) Represent cell viability data assessed 72 hours after treatment. Means of six replicates with standard errors are displayed. Measurements are normalized to DMSO controls. (B, D) Western blot analyses of p-Akt, p-ERK and p-S6 in isogenic murine (B) BRAF^V600E and (D) BRAF^WT cells. β-actin was used as loading control. Levels of p-Akt, p-ERK and p-S6 were determined 1 and 6 hours after treatment. For all of the above results, in samples receiving combination therapy, inhibitors were administered simultaneously.